The clinical activity of neoadjuvant immunochemotherapy for treating locally advanced oral squamous cell carcinoma (LA-OSCC) remains uncertain. In this single-arm, phase II trial, the authors show that neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin provides a favourable pathological response and manageable safety in patients with LA-OSCC while baseline CD4_Tfh_CXCL13 cells may serve as a predictive biomarker of efficacy.
- Zhongzheng Xiang
- Xiaoyuan Wei
- Lei Liu
